Please assess the completion status of the following clinical trial:

Trial Title: Pathophysiological Study of CSA in Adults With pLVEF

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male patient~* Age ≥18 years and ≤85 years~* With preserved LVEF heart failure (defined as LVEF ≥ 45% on ultrasound, MRI or isotopic ventriculography)~* Central SAS Group: Central to severe sleep apnea syndrome, defined by an apnea-hypopnoea index (IAH) greater than 15 per hour, of which at least 30% are central events;~* Obstructive SAS group: Moderate to severe obstructive sleep apnea syndrome, defined by an apnea-hypopnoea index (IAH) greater than 15 per hour, with a central event proportion of less than 30%~* Group snoring: absence of sleep apnea syndrome or mild sleep apnea syndrome (IAH \<15 / h) in polysomnography, and presence of snoring on at least 30% of the night of recording.~* Free, informed and written consent~* Patient affiliated to a social security scheme (beneficiary or beneficiary)~Exclusion Criteria:~* Impossibility of giving the subject informed information~* Participation in a research protocol involving the human person in the previous months if an exclusion directive is given in this protocol~* Use of respiratory or sedative depressant drugs, systemic corticosteroid therapy~* Impaired systolic function (defined by LVEF \<45% in ultrasound, MRI or isotopic ventriculography)~* Unstable cardiovascular disease (cardiovascular event of less than one month)~* Recent surgery of the ENT sphere (less than 6 months)~* Central neurological pathology known~* Known, severe respiratory pathology (severity left to the investigator's discretion)~* Renal insufficiency (creatinine clearance \<60 mL / min) or severe hepatic impairment~* Primary or secondary hemostasis disorder~* Patient on anticoagulant (antivitamin K, direct oral anticoagulant, heparin and related). Antiplatelet agents are allowed.~* Psychiatric pathology according to DSM-V criteria, unbalanced~* Pulsed saturation with oxyhemoglobin \<88% at rest, on awakening~* Allergy to lidocaine~* Patient under tutorship or curatorship~* Failure to perform a prior medical examination~* Tympanic perforation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Central SAS cases (Type: OTHER): Patients with central apnea
- Obstructive SAS controls (Type: OTHER): Patients with moderate to severe obstructive apnea (apnea-hypopnoea index ≥ 15 / h)
- Snorers controls (Type: OTHER): Snorers controls : Patients with snoring, with or without mild obstructive apneas (index of apnea-hypopneas \<15 / h)

Based on this trial design, predict the completion outcome and termination type (if applicable).